Skip to main content
Thermo Fisher enters CDx development partnership with Agios
5/19/2017

Thermo Fisher Scientific and Agios Pharmaceuticals have entered into an agreement under which a next-generation sequencing-based companion diagnostic will be developed and commercialized for Agios' investigational cancer drug ivosidenib. The companion diagnostic is intended for identifying IDH1 mutations using Thermo Fisher's Ion AmpliSeq technology, Ion PGM Dx system and Oncomine portfolio; the companies did not disclose additional terms of the deal.

Full Story: